Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome

Steven A. Schneider, William R. Sukov, Igor Frank, Stephen A. Boorjian, Brian A. Costello, Robert F. Tarrell, Prabin Thapa, R. Houston Thompson, Matthew K. Tollefson, R. Jeffrey Karnes, John C. Cheville

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

Micropapillary urothelial carcinoma exhibits amplification of the human epidermal growth factor receptor, ERBB2(HER2), and overexpression of the ERBB2 protein product. The clinical significance of this has yet to be established. The objective of this study was to examine ERBB2 amplification and protein expression in micropapillary urothelial carcinoma and stage-matched typical urothelial carcinoma treated by radical cystectomy to assess the frequency of amplification and protein expression, and to determine the association with cancer-specific survival. Pathologic material and data from patients undergoing cystectomy at Mayo Clinic between 1980 and 2008 were reviewed. ERBB2 amplification by fluorescence in situ hybridization (FISH) and protein expression by immunohistochemistry were assessed. Univariate and multivariate Cox proportional hazards regression models were used to evaluate for associations of ERBB2 amplification and protein expression with survival. ERBB2 amplification was identified in 9 (15%) of 61 micropapillary carcinomas compared with 9 (9%) of 100 urothelial carcinomas. In patients with micropapillary carcinoma, ERBB2 amplification was associated with a nearly threefold increased risk of cancer death. ERBB2 amplification (hazard ratio 4.3; P=0.0008) remained associated with an increased risk of death from bladder cancer among patients with micropapillary urothelial carcinoma on multivariate analysis. The association of cancer-specific survival and ERBB2 amplification was not seen in patients with urothelial carcinoma. ERBB2 immunohistochemistry correlated with ERBB2 amplification but there was no association of ERBB2 protein expression and survival. ERBB2 amplification is more frequent in micropapillary urothelial carcinoma than typical urothelial carcinoma, and patients with micropapillary carcinoma who have ERBB2 amplification have worse cancer-specific survival than those who do not. Identification of ERBB2 amplification in micropapillary carcinoma could provide important prognostic information and possibly provide a role for ERBB2 targeted therapy.

Original languageEnglish (US)
Pages (from-to)758-764
Number of pages7
JournalModern Pathology
Volume27
Issue number5
DOIs
StatePublished - May 2014

Keywords

  • ERBB2
  • bladder cancer
  • cystectomy
  • micropapillary
  • urothelial carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome'. Together they form a unique fingerprint.

  • Cite this

    Schneider, S. A., Sukov, W. R., Frank, I., Boorjian, S. A., Costello, B. A., Tarrell, R. F., Thapa, P., Houston Thompson, R., Tollefson, M. K., Jeffrey Karnes, R., & Cheville, J. C. (2014). Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Modern Pathology, 27(5), 758-764. https://doi.org/10.1038/modpathol.2013.201